NASDAQ:ALRN
Aileron Therapeutics
- Stock
Last Close
1.93
10/01 21:00
Market Cap
66.06M
Beta: 2.01
Volume Today
63.39K
Avg: 53.55K
PE Ratio
−1.68
PFCF: −1.64
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '15 | Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|---|
average inventory | ||||||||||
average payables | 1.31M - | 1.79M 36.72% | 1.67M 6.72% | 1.59M 4.44% | 1.52M 4.24% | 1.40M 7.94% | 1.47M 4.42% | 1.46M 0.68% | ||
average receivables | ||||||||||
book value per share | -172.83 - | -204.88 18.54% | 128.43 162.69% | 26.60 79.29% | 13.08 50.82% | 6.98 46.67% | 9.89 41.73% | 4.10 58.51% | 0.00 99.96% | |
capex per share | -0.17 - | -0.38 - | -6.00 1,473.03% | -0.12 97.95% | -0.00 97.67% | -0.04 1,132.80% | ||||
capex to depreciation | -0.29 - | -1.10 - | -20.29 1,743.15% | -0.97 95.20% | -0.03 96.85% | -1.30 4,129.92% | ||||
capex to operating cash flow | 0.01 - | 0.01 - | 0.16 2,189.97% | 0.01 96.40% | 0.00 95.72% | 0.01 2,606.69% | ||||
capex to revenue | ||||||||||
cash per share | 6.90 - | 37.96 449.76% | 136.37 259.27% | 28.08 79.41% | 14.90 46.95% | 7.92 46.85% | 10.34 30.63% | 4.68 54.76% | 0.00 99.92% | |
days of inventory on hand | ||||||||||
days payables outstanding | ||||||||||
days sales outstanding | ||||||||||
debt to assets | 0.18 - | 0.19 7.86% | 0.02 87.54% | 0.00 85.89% | 0.00 10.25% | 0.00 84.90% | ||||
debt to equity | 0.27 - | 0.31 15.05% | 0.03 89.85% | 0.00 88.40% | 0.00 3.95% | 0.01 96.66% | ||||
dividend yield | ||||||||||
earnings yield | -0.11 - | -0.15 40.73% | -0.29 87.41% | -2.55 784.39% | -2.05 19.66% | -0.60 70.61% | -0.52 14.36% | -2.51 387.24% | -0.00 99.96% | |
enterprise value | 114.11M - | 97.16M 14.85% | 66.59M 31.47% | 7.09M 89.36% | 13.78M 94.44% | 29.60M 114.82% | 46.56M 57.29% | 5.60M 87.98% | 14.01B 250,183.30% | |
enterprise value over ebitda | -9.08 - | -5.42 40.35% | -2.91 46.27% | -0.22 92.31% | -0.46 106.72% | -1.50 225.44% | -1.73 15.09% | -0.20 88.24% | -860.70 422,441.44% | |
ev to operating cash flow | -9.74 - | -6.47 33.59% | -3.24 49.88% | -0.25 92.18% | -0.52 105.10% | -1.45 177.75% | -1.96 35.58% | -0.23 88.52% | -707.23 314,080.84% | |
ev to sales | ||||||||||
free cash flow per share | -21.63 - | -27.51 27.19% | -55.55 101.91% | -43.90 20.97% | -21.70 50.56% | -11.75 45.87% | -5.38 54.16% | -5.48 1.72% | -0.00 99.92% | |
free cash flow yield | -0.10 - | -0.13 27.19% | -0.26 106.89% | -2.61 891.58% | -1.89 27.52% | -0.56 70.18% | -0.48 15.33% | -2.31 383.29% | -0.00 99.94% | |
graham net net | -176.81 - | -207.27 17.23% | 123.23 159.45% | 13.55 89.01% | 6.40 52.75% | 5.52 13.74% | 9.31 68.68% | 3.93 57.76% | 0.00 99.95% | |
graham number | 302.93 - | 391.26 29.16% | 418.95 7.08% | 160.06 61.79% | 83.10 48.08% | 44.32 46.66% | 35.93 18.94% | 23.44 34.77% | 0.01 99.95% | |
income quality | 0.91 - | 0.83 8.89% | 0.91 9.64% | 0.89 2.54% | 0.90 1.83% | 0.97 7.36% | 0.91 6.19% | 0.91 0.21% | 1.26 38.39% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.81 Infinity% | |
interest coverage | 86.94 - | |||||||||
interest debt per share | 7.25 - | 4.10 43.42% | 0.22 94.59% | 0.04 83.57% | -0.06 252.16% | 0.00 100.02% | ||||
inventory turnover | ||||||||||
invested capital | 0.27 - | 0.31 15.05% | 0.03 89.85% | 0.00 88.40% | 0.00 3.95% | 0.01 96.66% | ||||
market cap | 117.88M - | 117.88M 0% | 78.45M 33.45% | 12.38M 84.22% | 14.06M 13.56% | 36.26M 157.93% | 50.00M 37.88% | 10.76M 78.48% | 14.03B 130,275.92% | |
net current asset value | -96.23M - | -112.75M 17.17% | 46.95M 141.64% | 11.06M 76.44% | 9.13M 17.52% | 12.15M 33.12% | 43.60M 258.94% | 18.49M 57.59% | 10.55M 42.91% | |
net debt to ebitda | 0.30 - | 1.15 285.14% | 0.52 55.10% | 0.17 67.78% | 0.01 94.40% | 0.34 3,515.66% | 0.13 62.22% | 0.19 46.87% | 1.06 464.77% | |
net income per share | -23.60 - | -33.21 40.73% | -60.74 82.90% | -42.81 29.52% | -23.46 45.20% | -12.52 46.66% | -5.80 53.64% | -5.95 2.55% | -0.00 99.94% | |
operating cash flow per share | -21.46 - | -27.51 28.22% | -55.17 100.52% | -37.90 31.31% | -21.58 43.05% | -11.75 45.57% | -5.35 54.45% | -5.48 2.39% | -0.00 99.92% | |
payables turnover | ||||||||||
receivables turnover | ||||||||||
research and ddevelopement to revenue | ||||||||||
return on tangible assets | -2.17 - | -0.82 62.04% | -0.43 47.87% | -1.04 142.59% | -1.09 4.47% | -1.34 22.81% | -0.53 60.20% | -1.23 130.96% | -0.77 37.41% | |
revenue per share | ||||||||||
roe | 0.14 - | 0.16 18.72% | -0.47 391.76% | -1.61 240.34% | -1.79 11.43% | -1.79 0.03% | -0.59 67.29% | -1.45 147.16% | -2.28 57.49% | |
roic | 0.14 - | 0.16 18.90% | -0.48 396.22% | -1.07 121.30% | -1.12 5.54% | -1.68 49.81% | -0.59 64.89% | -1.46 146.78% | -2.35 60.80% | |
sales general and administrative to revenue | ||||||||||
shareholders equity per share | -172.83 - | -204.88 18.54% | 128.43 162.69% | 26.60 79.29% | 13.08 50.82% | 6.98 46.67% | 9.89 41.73% | 4.10 58.51% | 0.00 99.96% | |
stock based compensation to revenue | ||||||||||
tangible asset value | -94.32M - | -111.81M 18.54% | 47.80M 142.75% | 19.60M 58.99% | 16.05M 18.12% | 12.16M 24.21% | 43.90M 260.99% | 18.62M 57.58% | 12.77M 31.44% | |
tangible book value per share | -172.83 - | -204.88 18.54% | 128.43 162.69% | 26.60 79.29% | 13.08 50.82% | 6.98 46.67% | 9.89 41.73% | 4.10 58.51% | 0.00 99.93% | |
working capital | 1.48M - | 17.00M 1,051.12% | 46.95M 176.14% | 16.41M 65.06% | 13.71M 16.42% | 12.37M 9.81% | 43.67M 253.14% | 18.49M 57.66% | 13.88M 24.92% |
All numbers in USD (except ratios and percentages)